Cholinergic channel activator, ABT-418, enhances delayed response accuracy in rats

Alvin V Terry, J. J. Buccafusco, M. W. Decker

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The purpose of this study was to evaluate ABT-418, a recently developed isoxasole bioisostere of nicotine and cholinergic channel activator (ChCA), in rats trained to perform a delayed-response task, the Delayed Stimulus Discrimination Task (DSDT). In dose-effect studies, ABT-418 improved DSDT performance, while mecamylamine decreased accuracy of the task. The improvements afforded by optimal doses of ABT-418 were further substantiated by repeated administration on a separate occasion. Surprisingly, mecamylamine (1.0 mg/kg), when combined with optimal doses of ABT-418, failed to prevent improvements in accuracy of the task, as it had in a previous study with nicotine. The basis for this effect is unclear but may be related to the purported subtype selectivity of ABT-418. None of the drug-induced changes in DSDT accuracy was modality specific (i.e., whether the stimulus was the presented light or tone), and none of the drug manipulations produced significant changes in response latencies. Overall, the data confirm findings of previous rodent and nonhuman primate studies, which indicate that the nicotinic ligand has the potential to improve memory.

Original languageEnglish (US)
Pages (from-to)304-312
Number of pages9
JournalDrug Development Research
Volume40
Issue number4
DOIs
StatePublished - Apr 1 1997

Fingerprint

Cholinergic Agents
Mecamylamine
Nicotine
Task Performance and Analysis
Pharmaceutical Preparations
Primates
Reaction Time
Rodentia
3-methyl-5-(1-methyl-2-pyrrolidinyl)isoxazole
Ligands
Light
Discrimination (Psychology)

Keywords

  • Behaviour
  • Cognition
  • Memory
  • Nicotinic

ASJC Scopus subject areas

  • Drug Discovery

Cite this

Cholinergic channel activator, ABT-418, enhances delayed response accuracy in rats. / Terry, Alvin V; Buccafusco, J. J.; Decker, M. W.

In: Drug Development Research, Vol. 40, No. 4, 01.04.1997, p. 304-312.

Research output: Contribution to journalArticle

Terry, Alvin V ; Buccafusco, J. J. ; Decker, M. W. / Cholinergic channel activator, ABT-418, enhances delayed response accuracy in rats. In: Drug Development Research. 1997 ; Vol. 40, No. 4. pp. 304-312.
@article{1dd32ec4caf543ee8230b29c4da6b861,
title = "Cholinergic channel activator, ABT-418, enhances delayed response accuracy in rats",
abstract = "The purpose of this study was to evaluate ABT-418, a recently developed isoxasole bioisostere of nicotine and cholinergic channel activator (ChCA), in rats trained to perform a delayed-response task, the Delayed Stimulus Discrimination Task (DSDT). In dose-effect studies, ABT-418 improved DSDT performance, while mecamylamine decreased accuracy of the task. The improvements afforded by optimal doses of ABT-418 were further substantiated by repeated administration on a separate occasion. Surprisingly, mecamylamine (1.0 mg/kg), when combined with optimal doses of ABT-418, failed to prevent improvements in accuracy of the task, as it had in a previous study with nicotine. The basis for this effect is unclear but may be related to the purported subtype selectivity of ABT-418. None of the drug-induced changes in DSDT accuracy was modality specific (i.e., whether the stimulus was the presented light or tone), and none of the drug manipulations produced significant changes in response latencies. Overall, the data confirm findings of previous rodent and nonhuman primate studies, which indicate that the nicotinic ligand has the potential to improve memory.",
keywords = "Behaviour, Cognition, Memory, Nicotinic",
author = "Terry, {Alvin V} and Buccafusco, {J. J.} and Decker, {M. W.}",
year = "1997",
month = "4",
day = "1",
doi = "10.1002/(SICI)1098-2299(199704)40:4<304::AID-DDR4>3.0.CO;2-N",
language = "English (US)",
volume = "40",
pages = "304--312",
journal = "Drug Development Research",
issn = "0272-4391",
publisher = "John Wiley and Sons Inc.",
number = "4",

}

TY - JOUR

T1 - Cholinergic channel activator, ABT-418, enhances delayed response accuracy in rats

AU - Terry, Alvin V

AU - Buccafusco, J. J.

AU - Decker, M. W.

PY - 1997/4/1

Y1 - 1997/4/1

N2 - The purpose of this study was to evaluate ABT-418, a recently developed isoxasole bioisostere of nicotine and cholinergic channel activator (ChCA), in rats trained to perform a delayed-response task, the Delayed Stimulus Discrimination Task (DSDT). In dose-effect studies, ABT-418 improved DSDT performance, while mecamylamine decreased accuracy of the task. The improvements afforded by optimal doses of ABT-418 were further substantiated by repeated administration on a separate occasion. Surprisingly, mecamylamine (1.0 mg/kg), when combined with optimal doses of ABT-418, failed to prevent improvements in accuracy of the task, as it had in a previous study with nicotine. The basis for this effect is unclear but may be related to the purported subtype selectivity of ABT-418. None of the drug-induced changes in DSDT accuracy was modality specific (i.e., whether the stimulus was the presented light or tone), and none of the drug manipulations produced significant changes in response latencies. Overall, the data confirm findings of previous rodent and nonhuman primate studies, which indicate that the nicotinic ligand has the potential to improve memory.

AB - The purpose of this study was to evaluate ABT-418, a recently developed isoxasole bioisostere of nicotine and cholinergic channel activator (ChCA), in rats trained to perform a delayed-response task, the Delayed Stimulus Discrimination Task (DSDT). In dose-effect studies, ABT-418 improved DSDT performance, while mecamylamine decreased accuracy of the task. The improvements afforded by optimal doses of ABT-418 were further substantiated by repeated administration on a separate occasion. Surprisingly, mecamylamine (1.0 mg/kg), when combined with optimal doses of ABT-418, failed to prevent improvements in accuracy of the task, as it had in a previous study with nicotine. The basis for this effect is unclear but may be related to the purported subtype selectivity of ABT-418. None of the drug-induced changes in DSDT accuracy was modality specific (i.e., whether the stimulus was the presented light or tone), and none of the drug manipulations produced significant changes in response latencies. Overall, the data confirm findings of previous rodent and nonhuman primate studies, which indicate that the nicotinic ligand has the potential to improve memory.

KW - Behaviour

KW - Cognition

KW - Memory

KW - Nicotinic

UR - http://www.scopus.com/inward/record.url?scp=0030841542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030841542&partnerID=8YFLogxK

U2 - 10.1002/(SICI)1098-2299(199704)40:4<304::AID-DDR4>3.0.CO;2-N

DO - 10.1002/(SICI)1098-2299(199704)40:4<304::AID-DDR4>3.0.CO;2-N

M3 - Article

VL - 40

SP - 304

EP - 312

JO - Drug Development Research

JF - Drug Development Research

SN - 0272-4391

IS - 4

ER -